| 1 |
35251316 | Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. | 2022 |
1 |
| 2 |
34210314 | Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds. | 2021 Jul 1 |
1 |
| 3 |
31506897 | A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer. | 2020 Aug |
1 |
| 4 |
29024814 | Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. | 2017 Dec 28 |
4 |
| 5 |
26715098 | Targeting the PI3K signaling pathway in KRAS mutant colon cancer. | 2016 Feb |
2 |
| 6 |
27121230 | Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. | 2016 Jul |
3 |
| 7 |
25500057 | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. | 2015 Feb 15 |
1 |
| 8 |
22159814 | NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. | 2012 Apr |
2 |